|Bid||4.32 x 900|
|Ask||10.82 x 800|
|Day's Range||7.51 - 8.45|
|52 Week Range||7.42 - 36.00|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 09, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.20|
ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.'s ("Astellas") and Pfizer Inc.'s
Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..
Investment company Penn Series Small Cap Growth Fund (Current Portfolio) buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Rogers Corp, CarParts.com Inc, sells Guidewire Software Inc, Alarm.com Holdings Inc, Standex International Corp, H.B.